Nuclear imaging methods for non-invasive drug monitoring

被引:29
作者
Bhatnagar, A
Hustinx, R
Alavi, A
机构
[1] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
functional imaging; PET; SPECT;
D O I
10.1016/S0169-409X(99)00055-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional imaging techniques provide complimentary information to that provided by structural studies such as MRI and CT. Functional imaging is based upon known parameters such as physiology, metabolism, biochemistry, pharmacology, and any other biological process. As such, this methodology-plays a major role in understanding the basic mechanisms of a multitude of disorders, accurate diagnosis of certain diseases, and developing effective treatment for serious illnesses such as cancer and central nervous system maladies. Although this type of imaging can be performed with various modalities, nuclear procedures have played the leading role in this discipline. Advances made in labeling various radionuclides to biologically important compounds, and development of sophisticated instruments have substantially contributed to the growth of the field of functional imaging. The introduction of positron emission topography (PET), which is based on growth imaging of compounds labeled with elements such as carbon, nitrogen, and fluorine, has added a major dimension to the evolution of the discipline. This review deals with a brief introduction to the methodologies utilized with radiolabeled tracers and then deals with specific applications of this technology. These applications include assessment of blood flow and metabolism, receptor imaging, elucidating the pathophysiologic process, evaluating role of labeled therapeutic agents, and the potential of these techniques in the development of novel biologic therapies. Functional imaging with radiolabeled tracers will play an increasingly important role in modem medicine, and its impact will be substantial in the management of patients with various disorders. (C) 2000 Published by Elsevier Science B.V; All rights reserved.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 58 条
[1]  
BALLESTER M, 1994, MONOCLONAL ANTIBODIE, P70
[2]  
BIVER F, 1994, EUR J NUCL MED, V21, P937
[3]   A METHOD FOR THE INVIVO INVESTIGATION OF THE SEROTONERGIC 5-HT2 RECEPTORS IN THE HUMAN CEREBRAL-CORTEX USING POSITRON EMISSION TOMOGRAPHY AND F-18 LABELED SETOPERONE [J].
BLIN, J ;
SETTE, G ;
FIORELLI, M ;
BLETRY, O ;
ELGHOZI, JL ;
CROUZEL, C ;
BARON, JC .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (05) :1744-1754
[4]   STRIATAL D2 RECEPTOR STATUS IN PATIENTS WITH PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION, AND PROGRESSIVE SUPRANUCLEAR PALSY, MEASURED WITH C-11 RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY [J].
BROOKS, DJ ;
IBANEZ, V ;
SAWLE, GV ;
PLAYFORD, ED ;
QUINN, N ;
MATHIAS, CJ ;
LEES, AJ ;
MARSDEN, CD ;
BANNISTER, R ;
FRACKOWIAK, RSJ .
ANNALS OF NEUROLOGY, 1992, 31 (02) :184-192
[5]  
BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO
[6]  
2-X
[7]   F-18 DEOXYGLUCOSE UPTAKE IN SARCOIDOSIS MEASURED WITH POSITRON EMISSION TOMOGRAPHY [J].
BRUDIN, LH ;
VALIND, SO ;
RHODES, CG ;
PANTIN, CF ;
SWEATMAN, M ;
JONES, T ;
HUGHES, JMB .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1994, 21 (04) :297-305
[8]   Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer [J].
Bury, T ;
Dowlati, A ;
Paulus, P ;
Corhay, JL ;
Hustinx, R ;
Ghaye, B ;
Radermecker, M ;
Rigo, P .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2529-2534
[9]  
Cesano A, 1996, CANCER RES, V56, P3021
[10]   Cerebral vascular reactivity assessed with acetazolamide single photon emission computer tomography scans before and after carotid endarterectomy [J].
Cikrit, DF ;
Dalsing, MC ;
Harting, PS ;
Burt, RW ;
Lalka, SG ;
Sawchuk, AP ;
Solooki, B .
AMERICAN JOURNAL OF SURGERY, 1997, 174 (02) :193-197